TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis Therapy
Research on leishmaniasis therapy described by scientists at University of Heidelberg, Institute of Pharmacy and Molecular Biotechnology
September 23rd, 2008
Researchers detail in 'Leishmaniasis: drug resistance and natural products (review),' new data in leishmaniasis. "Epidemics of fatal visceral leishmaniasis caused by the intracellular protozoan Leishmania are a severe public health problem in tropical and subtropical regions of the world. One major drawback in the treatment of leishmaniasis is the emergence of resistance to current chemotherapeutics," scientists in Heidelberg, Germany report. "Leishmanicidals have to be administered in low doses since commonly used drugs exhibit severe side effects, and hence drug resistance can appear rapidly. Since, to date, vaccination approaches have failed to enter clinical trials,...
Source: TB & Outbreaks Week (2008-09-23)
|
